The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Progression-free survival (PFS) with lanreotide autogel/depot (LAN) in enteropancreatic NETs patients: The CLARINET extension study.
Martyn E. Caplin
Consultant or Advisory Role - Ipsen
Philippe B. Ruszniewski
Employment or Leadership Position - Ipsen (I)
Consultant or Advisory Role - Ipsen
Honoraria - Ipsen; Novartis
Research Funding - Ipsen; Novartis
Marianne E. Pavel
Consultant or Advisory Role - Ipsen; Lexicon; Novartis; Pfizer
Honoraria - Ipsen; Lexicon; Novartis; Pfizer
Research Funding - Novartis
Jaroslaw B. Cwikla
Research Funding - Ipsen
Alexandria T. Phan
Research Funding - Ipsen
Markus Raderer
Honoraria - Bayer; Celgene; Ipsen; Novartis; Pfizer; Roche
Eva Sedlackova
No relevant relationships to disclose
Guillaume Cadiot
Consultant or Advisory Role - Ipsen; Keocyt; Novartis
Honoraria - Ipsen; Keocyt; Novartis
Lucy R. Wall
No relevant relationships to disclose
Guido Rindi
Consultant or Advisory Role - Advanced Accelerator Applications; Ipsen; Novartis; Pfizer
Honoraria - Ipsen; Novartis; Pfizer
Alison Langley
Consultant or Advisory Role - Ipsen
Joelle Blumberg
Employment or Leadership Position - Ipsen